Book Value per Share: NexImmune (NEXI)

Graphic logo of NexImmune (NEXI)

NexImmune, Inc. is developing innovative cancer treatment methods. The book value per share helps filter out market noise, with the 1.99 mark characterizing this parameter. Financial stability is tied to the success of clinical trials in the absence of consistent revenue. The brand's scientific authority is based on its artificial antigen-presenting cell platform. The company is currently exploring strategic development options while increasing R&D expenditures.

NEXI: NexImmune Corp Net Asset Value per Share 07/04/2022 - 08/04/2024

neximmune.com - analytical breakdowns and key metrics (NEXI)

- price and consensus price forecast:
Stock Quotes NexImmune Corp|NEXI - Broker Consensus Forecast
- market capitalization data:
Market Capitalization NexImmune, Inc.|NEXI - Company Buyout Price
- book capitalization data:
Net Assets per Single Share NexImmune|NEXI - Total Stockholders' Equity|Market Value to Book Value Ratio neximmune.com|NEXI - Total Business Assets
- debt and liquidity data:
Total Debt to Capital NexImmune, Inc.|NEXI - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity NexImmune|NEXI - Company Cumulative Debt|Debt to Book Capitalization Ratio NexImmune, Inc.
Fundamental company valuation:NEXI - NexImmune Corp
Flagship merchandise of NexImmune

To stress-test positions, an investor must assess the residual value of assets minus all liabilities, which determines the issuer's actual internal reserve. Stable demand for the biomedical innovations of NexImmune, Inc. (NEXI) makes equity per share an indicator of business resilience, where growth in this metric confirms the accumulation of resources within an independent product cycle.

Competitor analysis for NexImmune, Inc.

ImmunityBio Corp (IBRX) - Accounting Value per Share|IMCR - Equity per Share|Janux Therapeutics - Book Value per Share|RCUS (arcusbio.com) - Net Assets per Share|Net Assets per Single Share ZYME (Zymeworks)|Net Asset Value per Share TNGX|Net Assets per Single Share Iovance IOVA|Equity per Share Immatics Biotechnologies (IMTX)|Xencor, Inc. - Book Value per Share|compasstherapeutics.com - Accounting Value per Share|REPL (Replimune) - Net Assets per Single Share|LYEL: Net Asset Value per Share|Innate Pharma, S.A. (IPHA) - Net Assets per Single Share|PYXS (Pyxis Oncology) - Net Assets per Single Share|Net Assets per Single Share CGEN (Compugen Ltd)|Net Asset Value per Share iobiotech.com|STRO: Book Value per Share|Book Value of One Share MiNK Therapeutics Inc. INKT|HOWL: Accounting Value per Share|IMMX - Net Asset Value per Share|Accounting Value per Share ALX Oncology Holdings (ALXO)|CUE - Accounting Value of a Share|pdsbiotech.com - Book Value per Share|SONN (Sonnet BioTherapeutics Holdings) - Net Assets per Share|Net Assets per Single Share MAIA|Accounting Value per Share LIMN|Net Assets per Single Share LVTX (LAVA Therapeutics N.V.)|Accounting Value per Share nextcure.com NXTC|Accounting Value per Share LPTX (Leap Therapeutics)|Intensity Therapeutics Inc - Book Value per Share|Sensei Bio (SNSE) - Net Assets per Single Share|TOVX: Equity per Share|Net Assets per Single Share GRTS|Net Asset Value per Share kinetabio.com|Turnstone Biologics Corp - Accounting Value per Share|Book Value of One Share Vaccinex Inc. (VCNX)|Accounting Value per Share Harpoon Tx